MTOR inhibitors in advanced renal cell carcinoma Journal Article
| Authors: | Voss, M. H.; Molina, A. M.; Motzer, R. J. |
| Article Title: | MTOR inhibitors in advanced renal cell carcinoma |
| Abstract: | Better understanding of the molecular biology of renal cell carcinoma (RCC) has led to the development of several targeted anti-cancer agents, several of which have since received approval for treatment of advanced disease. Two of these, the intravenous agent temsirolimus and the oral everolimus, exhibit antitumor effects through inhibition of the mammalian target of rapamycin (mTOR) pathway. This article reviews their mechanisms of action in the context of the current understanding of RCC pathophysiology, the clinical data leading to their approval, class-specific toxicities, potential molecular mechanisms behind treatment resistance and novel treatment approaches for RCC that incorporate mTOR blockade. © 2011 Elsevier Inc. |
| Keywords: | immunohistochemistry; signal transduction; epidermal growth factor; mitogen activated protein kinase; protein kinase b; protein expression; treatment outcome; constipation; fatigue; neutropenia; review; sorafenib; bevacizumab; sunitinib; advanced cancer; diarrhea; hypophosphatemia; side effect; clinical trials as topic; binding affinity; anorexia; stat3 protein; drug eruption; infection; pain; anemia; nausea; stomatitis; thrombocytopenia; vomiting; protein binding; creatinine blood level; antineoplastic activity; immunoreactivity; phosphatidylinositol 3 kinase; renal cell carcinoma; kidney carcinoma; kidney neoplasms; temsirolimus; abdominal pain; aspartate aminotransferase blood level; asthenia; coughing; drug fever; dyspnea; hyperglycemia; lymphocytopenia; pneumonia; pruritus; protein kinase inhibitors; drug induced headache; drug mechanism; carcinoma, renal cell; protein synthesis; myc protein; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; peripheral edema; initiation factor 4e; initiation factor 4e binding protein 1; targeted therapy; somatomedin c; hypercholesterolemia; mammalian target of rapamycin inhibitor; cyclin d1; hypoxia inducible factor 1alpha; serum and glucocorticoid regulated kinase 1; epistaxis; everolimus; phosphatidylinositol 3,4,5 trisphosphate; rapamycin; octamer transcription factor 4; hyperlipidemia; sirolimus; von hippel lindau protein; calcium cell level; fibroblast growth factor; mtor; transforming growth factor alpha; dysgeusia; phase 3 clinical trial (topic); mammalian target of rapamycin complex 1; treatment resistance; tor serine-threonine kinases; mammalian target of rapamycin complex 2; hypoxia inducible factor 2alpha; phosphatidylinositol 4,5 bisphosphate; tivozanib |
| Journal Title: | Hematology/Oncology Clinics of North America |
| Volume: | 25 |
| Issue: | 4 |
| ISSN: | 0889-8588 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2011-08-01 |
| Start Page: | 835 |
| End Page: | 852 |
| Language: | English |
| DOI: | 10.1016/j.hoc.2011.04.008 |
| PROVIDER: | scopus |
| PUBMED: | 21763970 |
| PMCID: | PMC3587783 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 17 August 2011" - "CODEN: HCNAE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work